bupropion has been researched along with Suicidal Ideation in 13 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Suicidal Ideation: A risk factor for suicide attempts and completions, it is the most common of all suicidal behavior, but only a minority of ideators engage in overt self-harm.
Excerpt | Relevance | Reference |
---|---|---|
" This study explored whether anxiety predicts suicidal ideation in depressed individuals treated with paroxetine or bupropion." | 9.27 | Effects of anxiety on suicidal ideation: exploratory analysis of a paroxetine versus bupropion randomized trial. ( Burke, AK; Chaudhury, SR; Ellis, SP; Grunebaum, MF; Keilp, JG; Mann, JJ; Marver, JE; Metts, AV; Oquendo, MA; Parris, MS, 2018) |
"The authors reanalyzed data from the 17 placebo-controlled randomized controlled trials (N=8,027) of varenicline conducted by Pfizer, using complete intent-to-treat person-level longitudinal data to assess smoking abstinence and reports of suicidal thoughts and behavior, depression, aggression/agitation, and nausea and to compare effects in patients with (N=1,004) and without (N=7,023) psychiatric disorders." | 7.79 | Varenicline, smoking cessation, and neuropsychiatric adverse events. ( Gibbons, RD; Mann, JJ, 2013) |
"This report used acute treatment data from a clinically representative sample of outpatients with nonpsychotic major depressive disorder (N = 665) participating in the Combining Medications to Enhance Depression Outcomes trial, who received up to 12 weeks of escitalopram, escitalopram plus bupropion SR, or venlafaxine XR plus mirtazapine." | 5.30 | The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. ( Carmody, TJ; De La Garza, N; Grannemann, BD; Killian, MO; Rush, AJ; Trivedi, MH, 2019) |
"In a randomized clinical trial comparing paroxetine and bupropion for treatment of depression in patients with either suicidal ideation or past attempt, depression severity and suicidal ideation were assessed weekly during the 8-week study." | 5.27 | Suicidal ideation declines with improvement in the subjective symptoms of major depression. ( Burke, AK; Ellis, SP; Gorlyn, M; Grunebaum, MF; Keilp, JG; Mann, JJ; Oquendo, MA, 2018) |
" This study explored whether anxiety predicts suicidal ideation in depressed individuals treated with paroxetine or bupropion." | 5.27 | Effects of anxiety on suicidal ideation: exploratory analysis of a paroxetine versus bupropion randomized trial. ( Burke, AK; Chaudhury, SR; Ellis, SP; Grunebaum, MF; Keilp, JG; Mann, JJ; Marver, JE; Metts, AV; Oquendo, MA; Parris, MS, 2018) |
" We conducted a double-blind, randomized, clinical pilot trial of paroxetine (N=36) or bupropion (N=38) in DSM IV major depression with a suicide attempt history or current suicidal ideation." | 5.16 | Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression. ( Burke, AK; Duan, N; Ellis, SP; Grunebaum, MF; John Mann, J; Oquendo, MA, 2012) |
"The authors reanalyzed data from the 17 placebo-controlled randomized controlled trials (N=8,027) of varenicline conducted by Pfizer, using complete intent-to-treat person-level longitudinal data to assess smoking abstinence and reports of suicidal thoughts and behavior, depression, aggression/agitation, and nausea and to compare effects in patients with (N=1,004) and without (N=7,023) psychiatric disorders." | 3.79 | Varenicline, smoking cessation, and neuropsychiatric adverse events. ( Gibbons, RD; Mann, JJ, 2013) |
"Reduced suicidal ideation was best predicted by a combination of the independent improvements in both depression symptomatology and verbal memory." | 2.80 | Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs. bupropion. ( Burke, A; Gorlyn, M; Grunebaum, M; Keilp, J; Mann, JJ; Oquendo, M, 2015) |
"Prior studies have suggested that major depressive disorder (MDD) with pre-adult onset represents a distinct subtype with greater symptom severity and higher rates of suicidal ideation." | 2.78 | Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. ( Balasubramani, GK; Kurian, B; Rush, AJ; Sung, SC; Trivedi, MH; Warden, D; Wisniewski, SR; Zisook, S, 2013) |
"Baseline suicidal ideation was associated with greater depressive severity, childhood neglect, childhood abuse, early major depressive disorder onset, greater psychiatric comorbidity, and worse functioning and quality of life." | 2.76 | Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. ( Fava, M; Kallenberg, G; Lebowitz, B; Lesser, IM; Luther, JF; Morris, DW; Nierenberg, AA; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2011) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 12 (92.31) | 24.3611 |
2020's | 1 (7.69) | 2.80 |
Authors | Studies |
---|---|
Weissman, CR | 1 |
Hadas, I | 1 |
Yu, D | 1 |
Jones, B | 1 |
Kong, D | 1 |
Mulsant, BH | 1 |
Blumberger, DM | 1 |
Daskalakis, ZJ | 2 |
Keilp, JG | 3 |
Ellis, SP | 4 |
Gorlyn, M | 2 |
Burke, AK | 4 |
Oquendo, MA | 4 |
Mann, JJ | 5 |
Grunebaum, MF | 4 |
Parris, MS | 1 |
Marver, JE | 1 |
Chaudhury, SR | 1 |
Metts, AV | 1 |
Lewis, CP | 1 |
Camsari, DD | 1 |
Sonmez, AI | 1 |
Nandakumar, AL | 1 |
Gresbrink, MA | 1 |
Croarkin, PE | 1 |
De La Garza, N | 1 |
Rush, AJ | 3 |
Killian, MO | 1 |
Grannemann, BD | 1 |
Carmody, TJ | 1 |
Trivedi, MH | 3 |
Gibbons, RD | 1 |
Sudol, K | 1 |
Bauer, N | 1 |
Keilp, J | 1 |
Burke, A | 1 |
Oquendo, M | 1 |
Grunebaum, M | 1 |
Duan, N | 1 |
John Mann, J | 1 |
Zisook, S | 2 |
Lesser, IM | 1 |
Lebowitz, B | 1 |
Kallenberg, G | 1 |
Wisniewski, SR | 2 |
Nierenberg, AA | 1 |
Fava, M | 2 |
Luther, JF | 1 |
Morris, DW | 1 |
Perlis, RH | 1 |
Uher, R | 1 |
Perroud, N | 1 |
Sung, SC | 1 |
Balasubramani, GK | 1 |
Kurian, B | 1 |
Warden, D | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized Controlled Trial of Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents With Suicidal Ideation Associated With Major Depressive Disorder[NCT04502758] | 80 participants (Anticipated) | Interventional | 2022-04-04 | Recruiting | |||
Combining Medications to Enhance Depression Outcomes[NCT00590863] | Phase 4 | 665 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
Paroxetine Versus Bupropion for Suicide Ideators or Attempters With Major Depressive Disorder[NCT00429169] | Phase 4 | 101 participants (Actual) | Interventional | 2004-06-30 | Terminated (stopped due to Interim analysis showed differential treatment effects.) | ||
SSRI Versus Bupropion in High-Risk Major Depressive Disorder[NCT01748955] | Phase 4 | 15 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. (NCT00590863)
Timeframe: Measured at Month 7
Intervention | units on a scale (Mean) |
---|---|
Escitalopram + Bupropion SR | 0.6 |
Venlafaxine XR + Mirtazapine | 0.4 |
Escitalopram + Placebo | 0.4 |
Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). (NCT00590863)
Timeframe: Measured at Month 7
Intervention | percentage of participants (Number) |
---|---|
Escitalopram + Bupropion SR | 46.6 |
Venlafaxine XR + Mirtazapine | 41.8 |
Escitalopram + Placebo | 46.0 |
"Comparison of fMRI results at baseline and after 8 weeks of antidepressant pharmacotherapy with paroxetine vs. bupropion.~Percent change in contrast of parameter estimates (COPE). COPE is measured during Monetary Incentive Delay Task.~Task conditions are:~Reward=BOLD signal when subject wins 5 cents vs. wins 0 cents Punishment=BOLD signal when subject loses 5 cents vs. loses 0 cents" (NCT00429169)
Timeframe: Baseline and Week 8.
Intervention | percentage of change in COPE (Mean) |
---|---|
Paroxetine | -0.27 |
Bupropion | -0.95 |
Change in neuropsychological measure of impulsivity. Computer-based task involving induction of a dominant response tendency and testing of the subject's ability to withhold responding to less frequent non-target stimuli. (NCT00429169)
Timeframe: Measured at Baseline and Week 8
Intervention | Commission errors (Mean) |
---|---|
Paroxetine | -0.09 |
Bupropion | -0.06 |
Suicide attempts, other suicidal behavior, or increase in suicidal thoughts that required a change in clinical treatment. (NCT00429169)
Timeframe: Measured at Month 6
Intervention | Events (Number) |
---|---|
Paroxetine | 4 |
Bupropion | 6 |
The clinician-rated Beck Scale for Suicidal Ideation (SSI) (Beck et al 1979)was used weekly for 8 weeks. It has 19 items scaled 0 (least severe) to 2 (most severe) and total score is the sum, ranging 0 to 38 (Beck et al 1979). Items measure frequency, intensity, and attitudes toward suicidal thoughts, feelings of control over them, and suicide plans. Mean score in 90 inpatients hospitalized for suicidal ideation was 9.4±8.4, versus 4.4±5.8 in outpatients as cited in the study by Beck et al, 1979. (NCT00429169)
Timeframe: Baseline and Week 8
Intervention | Points on Scale for Suicidal Ideation (Mean) | |
---|---|---|
Baseline | Week 8 | |
Bupropion | 9.9 | 4.7 |
Paroxetine | 8.0 | 2.3 |
Beck Scale of Suicidal Ideation Minimum Value = 0 Maximum Value = 38 Higher score is more severe suicidal thoughts (NCT01748955)
Timeframe: Measured at Baseline and Week 8
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline | Week 8 | |
Bupropion | 11 | 3.3 |
Paroxetine CR | 4.8 | 0.3 |
"% change in COPE = (Post-treatment COPE - Pre-treatment COPE) / Pre-treatment COPE COPE is measured during Monetary Incentive Delay Task.~Task conditions are:~Reward= BOLD signal when subject wins 5 cents vs. wins 0 cents Punishment= BOLD signal when subject loses 5cents vs. loses 0 cents" (NCT01748955)
Timeframe: Measured at Baseline (pre-treatment) and Week 8 (post-treatment)
Intervention | Percentage change (Mean) | |||
---|---|---|---|---|
ACC Reward | ACC Punishment | Amygdala Reward | Amygdala Punishment | |
Bupropion | 0.29 | -1.19 | -0.90 | -0.32 |
Paroxetine CR | -2.12 | -1.33 | -0.87 | -0.66 |
8 trials available for bupropion and Suicidal Ideation
Article | Year |
---|---|
Suicidal ideation declines with improvement in the subjective symptoms of major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Female; Huma | 2018 |
Effects of anxiety on suicidal ideation: exploratory analysis of a paroxetine versus bupropion randomized trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Delayed-Action Preparations; De | 2018 |
The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation.
Topics: Adult; Aged; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Drug Therapy, Combinatio | 2019 |
SSRI versus bupropion effects on symptom clusters in suicidal depression: post hoc analysis of a randomized clinical trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depre | 2013 |
Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs. bupropion.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cognition Disorders; Depressive Disorder | 2015 |
Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression.
Topics: Adolescent; Adult; Affect; Aged; Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors; | 2012 |
Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression.
Topics: Adolescent; Adult; Affect; Aged; Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors; | 2012 |
Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression.
Topics: Adolescent; Adult; Affect; Aged; Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors; | 2012 |
Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression.
Topics: Adolescent; Adult; Affect; Aged; Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors; | 2012 |
Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Citalopram; Cyclohexanols; Delayed-Action | 2011 |
Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
Topics: Adolescent; Adult; Age of Onset; Aged; Antidepressive Agents, Second-Generation; Bupropion; Child Ab | 2013 |
5 other studies available for bupropion and Suicidal Ideation
Article | Year |
---|---|
Predictors of change in suicidal ideation across treatment phases of major depressive disorder: analysis of the STAR*D data.
Topics: Antidepressive Agents; Bupropion; Depressive Disorder, Major; Depressive Disorder, Treatment-Resista | 2021 |
Preliminary evidence of an association between increased cortical inhibition and reduced suicidal ideation in adolescents treated for major depression.
Topics: Adolescent; Adolescent Behavior; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; De | 2019 |
Varenicline, smoking cessation, and neuropsychiatric adverse events.
Topics: Adult; Aggression; Akathisia, Drug-Induced; Benzazepines; Bupropion; Depression; Female; Humans; Mal | 2013 |
New obesity pill: new hopes, old fears.
Topics: Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Bupropion; Cardiovascular Diseases; D | 2010 |
Do suicidal thoughts or behaviors recur during a second antidepressant treatment trial?
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Buspirone; Citalopram; Cognitive Behavio | 2012 |